Overview
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Status:
Completed
Completed
Trial end date:
2022-11-30
2022-11-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
Steroid-refractory graft-vs-host disease (SR-GVHD) is a major cause of mortality after allogeneic hematopoietic stem cell transplantation (HSCT). We sought to evaluate the effect and safety of ruxolitinib (RUX) add-on in the treatment of patients with SR-GVHD.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Yi-Lun Wang
Criteria
Inclusion Criteria:- Patients diagnosed with hematologic disorder
Exclusion Criteria:
- Those who are not applicable of receiving Ruxolitinib as immunodeficiency-modulation
therapy
- Those who are actively encountering acute infectious illness